The mitochondrial-derived exercise mimetic — how it activates AMPK, improves metabolism, and why researchers call it the "exercise pill."
MOTS-C is a 16 amino acid mitochondrial-derived peptide encoded in the mitochondrial DNA (12S rRNA gene). Unlike most peptides which are encoded in nuclear DNA, MOTS-C originates from the mitochondria — the cell’s energy-producing organelles.
Identified in 2015 by researchers at the University of Southern California, MOTS-C has been called an “exercise mimetic” because it activates many of the same metabolic pathways as physical exercise. Natural MOTS-C levels increase roughly 12-fold during exercise, and decline significantly with age.
MOTS-C works primarily by activating AMPK, the body’s master metabolic switch. This triggers a cascade of effects including improved insulin sensitivity, enhanced fat metabolism, and increased cellular energy production.
Not FDA approved. WADA prohibited under S4.5 Metabolic Modulators (AMPK activators) — MOTS-c was added as a named example on the 2025 list, in force from 1 January 2025. Available through research peptide suppliers.
MOTS-C activates AMP-activated protein kinase (AMPK), the master energy sensor. AMPK activation shifts cells toward catabolic (energy-producing) metabolism — the same switch flipped by exercise and caloric restriction.
Inhibits the folate cycle, redirecting cellular metabolism. This contributes to its effects on fat oxidation and glucose utilization.
Under metabolic stress, MOTS-C translocates from the mitochondria to the nucleus where it directly regulates gene expression — a rare and significant form of mito-nuclear communication.
Primarily targets skeletal muscle tissue, improving glucose uptake and fatty acid oxidation in muscle cells — mirroring the metabolic adaptations of regular exercise.
Natural MOTS-C increases ~12-fold during exercise. Exogenous MOTS-C activates many of the same pathways, earning it the label “exercise in a peptide” — though it is not a replacement for physical activity.
MOTS-C research is still emerging, but preclinical results have been compelling enough to prompt human clinical trials (CB4211 Phase 1).
| Benefit | Evidence |
|---|---|
| Insulin sensitivity | AMPK activation improves glucose uptake in skeletal muscle; key mechanism for metabolic health |
| Fat metabolism | Prevents diet-induced obesity in animal models; enhances fatty acid oxidation |
| Physical performance | Improved exercise capacity in aged mice; enhances muscle adaptation to training |
| Anti-aging | Endogenous levels decline with age; supplementation reverses age-related metabolic decline in animal models |
| Cardiovascular | Supports healthy endothelial function and vascular health via AMPK-mediated pathways |
| Bone health | Research suggests positive effects on bone metabolism and osteoblast activity |
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeMOTS-C comes as a lyophilized powder. Use bacteriostatic water and standard reconstitution technique.
5 mg vial + 1 mL BAC water = 5 mg/mL
| Dose | Volume | Syringe Units |
|---|---|---|
| 200 mcg | 0.04 mL | 4 units |
| 500 mcg | 0.10 mL | 10 units |
| 5 mg (full dose) | 1.00 mL | 100 units (full syringe) |
5 mg vial at 5 mg per dose = 1 dose per vial
Pre-filled with a typical MOTS-C setup. Edit any field — the draw updates live.
Dose requires 1.000 ml but your 0.5 ml syringe can't hold that much. Use a larger syringe or add more BAC water.
Free account. Saves your reconstitution + schedules doses + tracks every vial.
Dosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
How fast does it work?
Energy and endurance improvements often noticed within the first 1 – 2 weeks. Metabolic and body composition changes develop over 4 – 8 weeks.
Can it replace exercise?
No. MOTS-C enhances the benefits of exercise and activates some of the same pathways, but it is not a substitute for physical activity. Best results come from pairing the two.
What biomarkers should I track?
Fasting glucose, HbA1c, fasting insulin, body composition, and exercise performance metrics. StackTrax can help you log and monitor these over time.
Why morning, fasted?
Natural MOTS-C levels peak with exercise and fasting. Morning fasted dosing aligns with the body’s natural rhythm and maximizes AMPK activation.
Looking for MOTS-C? We recommend NextGen Peptides — third-party tested, fast shipping, and trusted by the StackTrax community.
10% off with code
Exclusive StackTrax discount
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeNo. MOTS-c has never been FDA approved and has never been the subject of any human interventional trial. The only completed clinical trial of a MOTS-c-related molecule (CB4211, a synthetic MOTS-c analog by CohBar, NCT03998514) used a different molecule, was a Phase 1a/1b safety study, and the program was discontinued. MOTS-c is sold only as a research chemical.
The most-cited community protocol is 5 mg subcutaneously every 5 days, in a 20-day cycle, 2–4 times per year. This is community/clinic empiricism — there is no human-trial-derived dose for MOTS-c. Anti-aging clinics began offering MOTS-c around 2018–2020 with effectively arbitrary protocols that converged via word-of-mouth, and the current dose is the result of that convergence rather than dose-finding science.
A typical reconstitution is 10 mg of MOTS-c + 2 mL of bacteriostatic water, yielding 5 mg/mL. A 5 mg dose draws to 1.00 mL (full 100-unit insulin syringe). Many users prefer a 10 mg + 5 mL = 2 mg/mL ratio so a 5 mg dose becomes 2.5 mL — easier draw on a 3 mL syringe, gentler subcutaneous injection volume.
In rodents, MOTS-c activates AMPK, improves insulin sensitivity, increases fatty-acid oxidation, increases exercise capacity, and reduces obesity-induced metabolic dysfunction (Lee 2015 PMID 25738459; Reynolds 2021 PMID 33473109). Primary target tissue in animal work is skeletal muscle. Whether any of this translates to humans is unknown — no human RCT exists.
MOTS-c is a mitochondrially-derived peptide (encoded in mitochondrial DNA, not nuclear DNA). It is one of a small group of "MDPs" — mitochondrial-derived peptides like humanin and the SHLPs. Most peptides used in community protocols (BPC-157, growth hormone secretagogues, GLP-1 agonists) are nuclear-derived or fully synthetic — MOTS-c is biologically a different category, which is part of what drives the anti-aging and longevity interest.
Yes. MOTS-c is captured by WADA S0 (Non-Approved Substances) as a non-approved peptide. No therapeutic-use exemption is available.
Disclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor. This page contains affiliate links — StackTrax may earn a commission on purchases at no extra cost to you.
© 2026 StackTrax, LLC. All rights reserved.
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.
These pages also contain affiliate links. We may earn a commission on purchases at no extra cost to you — this never changes our editorial recommendations.